Ignite Creation Date:
2024-05-06 @ 2:59 AM
Last Modification Date:
2024-10-26 @ 11:26 AM
Study NCT ID:
NCT02176876
Status:
COMPLETED
Last Update Posted:
2015-06-29
First Post:
2014-06-25
Brief Title:
Safety Tolerability and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
A Phase 1b Double-Blind Randomized Placebo-Controlled Multicenter Study Evaluating the Safety Tolerability and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to assess the safety tolerability and pharmacokinetics PK of multiple infusions of GS-5745 in adults with rheumatoid arthritis RA Participants will be randomized in a 41 ratio to receive 1 intravenous IV infusion of GS-5745 or placebo every 2 weeks for a total of 3 IV infusions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-005396-41 | EUDRACT_NUMBER | None | None |